| Literature DB >> 31109718 |
Edgar Ortiz-Brizuela1, Francisco Leal-Vega2, Jennifer Cuellar-Rodríguez3, Miriam Bobadilla-Del-Valle2, Alfredo Ponce-de-León4.
Abstract
A 49-year-old kidney transplant recipient, presented with a skin rash, and interstitial infiltrates three weeks after receiving a live attenuated varicella-zoster vaccine. Varicella-zoster Oka-vaccine strain was detected in plasma by polymerase chain reaction and sequencing analysis targeting open reading frame 62 (ORF 62). She was treated successfully with intravenous acyclovir. Our case report supports the current contraindication of live attenuated varicella-zoster vaccine in the solid-organ transplant recipients. Recombinant subunit varicella-zoster vaccine may be the vaccine of choice in these patients; nevertheless, further information is required to establish its safety, efficacy, and optimal timing.Entities:
Keywords: Herpes zoster; Kidney transplantation; Shingles; Shingrix; Solid organ transplantation; Zostavax; Zoster vaccine
Year: 2019 PMID: 31109718 DOI: 10.1016/j.vaccine.2019.05.017
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641